Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Autolus Therapeutics's AUTO-8?
AUTO-8 is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Phase I program in Relapsed Multiple Myeloma;Refractory...
AUTO-8 by Autolus Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
AUTO-8 is under clinical development by Autolus Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...
AUTO-8 by Autolus Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
AUTO-8 is under clinical development by Autolus Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData,...